A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs Entrectinib (Primary) ; Midazolam
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Ignyta; Roche
- 17 Aug 2018 Status changed from active, no longer recruiting to completed.
- 13 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Jun 2018 Planned End Date changed from 1 Sep 2018 to 22 Aug 2018.